SIRPα + CD209 + cells could be a biomarker for antigen-presenting capacity, and enhancing their APC function could potentially improve RT/PD1 effectiveness by combination with anti- SIRPα in CRC. This evidence concerns the gene SIRPA and colorectal carcinoma.